vimarsana.com

Latest Breaking News On - Samantha semenkow - Page 2 : vimarsana.com

Editas Medicine, Inc (NASDAQ:EDIT) Q4 2023 Earnings Call Transcript

Editas Medicine, Inc. beats earnings expectations. Reported EPS is $-0.23, expectations were $-0.52.

United statesCristi barnettSamantha semenkowBrian chengErick luceraJoon leeBaisong meiGilmore oneillCaren deardorfGreg harrisonLinda burklyEditas medicine incCorporate communicationsVertex pharmaceuticalsMost valuable electric car companiesEditas medicine

Citi Downgrades NGM Biopharmaceuticals (NGM) to Neutral

Citi Downgrades NGM Biopharmaceuticals (NGM) to Neutral
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Samantha semenkowColumn groupAtlas neon parentAtlas neon merger subHigh risk

Citi Starts Prime Medicine (PRME) at Neutral

Citi Starts Prime Medicine (PRME) at Neutral
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Samantha semenkowPrime medicine

Editas Medicine, Inc (NASDAQ:EDIT) Q3 2023 Earnings Call Transcript

Operator: Good morning, and welcome to Editas Medicine s Third Quarter Conference Call. All participants are now in listen-only mode.

Baisong meiGilmore oneillSamantha semenkowCaren deardorfCristi barnettLinda berkleyLinda burklyJoon leeErick luceraBrian chengHarvard universityCorporate communicationsEuropean hematology association congressBroad institute casEditas medicine incEditas medicine

This little-known biotech stock has blockbuster potential, says Citi

The bank predicts Cabaletta's autoimmune disease treatment could help shares soar more than 65% from Friday's close.

Samantha semenkowMorgan stanleyCabaletta bioAnalyst samantha semenkowCabaletta bio incStock marketsWall streetBreaking news investingBusiness news

vimarsana © 2020. All Rights Reserved.